Metrics as of 10/16/2026, 08:42 AM (Berlin time), refresh in progress.
Valion Bio Stock
Valion Bio, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Michael R. Cavanaugh
- Employees
- 52
- Market cap
- $2 M
- IPO
- 11/11/2021
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an…
Valion Bio stock: price history
1D
-15.2%
1W
-44.3%
1M
-41.7%
6M
-95.6%
YTD
-96.6%
1Y
-98.4%
2Y
-98.7%
5Y
–
10Y
–
Next earnings date
Next earnings date
13/11/2026 (in 27 days)
Volatility around earnings
~29% stronger price swings than usual
Ask the agents about Valion Bio
Valion Bio stock metrics
P/E
-0.02
P/B
0.01
EV/EBITDA
-1.12
RETURN ON EQUITY
-59.8%
NET MARGIN
0.0%
DEBT/EQUITY
1.46
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
99.8%
FLOAT SHARES
1,943,901
AVG. DAILY VOLUME (30D)
2,813,571
Insider transactions (SEC)
Wolf Lisa G
Wolf Lisa G
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Valion Bio stock
What does Valion Bio do?
Valion Bio, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Michael R. Cavanaugh, the company employs around 52 people.
The IPO was on 11/11/2021; the stock trades on NASDAQ under the ticker VBIO.
When does Valion Bio report next?
The next earnings date is 13/11/2026.
Around past earnings, price swings were roughly 29% stronger than usual.
Does Valion Bio pay a dividend?
No, Valion Bio currently does not pay a dividend.
Which stocks are comparable to Valion Bio?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Valion Bio stock analyzed?
Clicking "Analyze stock" lets five strategies assess Valion Bio against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.